US scientists find possible therapeutic treatment for coronavirus

The study, published in the journal Science Translational Medicine, has found that small molecule protease inhibitors show potency against human coronaviruses

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
These coronavirus 3C-like proteases are strong therapeutic targets because they play vital roles in coronavirus replication
Press Trust of India Washington
2 min read Last Updated : Aug 05 2020 | 12:52 AM IST

Scientists in the US have found a potential therapeutic treatment for SARS-CoV-2, the virus that causes Covid-19, and other coronaviruses.

Pathogenic coronaviruses are a major threat to global public health, as shown by the SARS-CoV, MERS-CoV, and the newly emerged SARS-CoV-2.

The study, published in the journal Science Translational Medicine, has found that small molecule protease inhibitors show potency against human coronaviruses.

ALSO READ: Hope for vaccine: Coronavirus strains show little variability, study finds

These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication, the researchers said.

"Vaccine developments and treatments are the biggest targets in Covid-19 research, and treatment is really key," said Kyeong-Ok Chang, a professor at Kansas State University in the US.

"This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target," Chang said.

The study demonstrates that this series of optimised coronavirus 3CLpro inhibitors blocked replication of the human coronaviruses MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS, the researchers said.

These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection, they said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineScientistsCOVID-19

Next Story